Last month, the European Parliament’s Health Committee introduced amendments to Supplementary Protection Certificate (SPC) manufacturing waivers. On December 4, 2018, the committee voted in favor of the amendments.
Last month, the European Parliament’s Health Committee (ENVI) introduced amendments to Supplementary Protection Certificate (SPC) manufacturing waivers. On December 4, 2018, the committee voted in favor of the amendments.
Trade group Medicines for Europe praised the vote, saying in a statement that its board “unanimously applauds last night’s vote in the European Parliament where, once again, parliamentarians voted for a comprehensive Supplementary Protection Certificate manufacturing waiver. This has the potential of unlocking huge industrial job opportunities and healthcare savings as SPCs expire on blockbuster medicines over the next few years.”
The proposed amendments called for revising SPCs to boost the development and manufacturing of biosimilars and generics. The original SPC waivers were an intellectual property right that granted an extension of up to 5 years on a 20-year patent term for an innovative pharmaceutical.
The amendments sought to introduce a manufacturing exemption for export purposes during the term of an SPC that would restrict the protection in order to remove competitive disadvantages to European Union (EU)-based generic and biosimilar developers. The amendments allow a drug maker to manufacture a product in an EU member state for the purpose of exporting a product to a non-EU market that is not subject to an SPC. Additionally, the proposals favor of “day 1” launches of drugs after SPC expiry.
During the vote on Tuesday, the International Trade Committee (INTA) “confirmed the opinion of the Health Committee by introducing the possibility of ‘day 1’ launch to allow manufacturing for European patients and by removing requirements to disclose confidential business information under the notification procedure.”
Adrian van den Hoven, director general of Medicines for Europe, commented “We thank the Trade Committee for not caving in to vested interests and foreign pressure by voting for a comprehensive SPC manufacturing waiver…The manufacturing waiver is the first step in a policy to ensure Europe’s security of supply of medicines, to stop the delocalization of production and to stimulate competition after SPC expiry.”
Medicines for Europe has now called on Parliament’s Legal Committee to adopt the amendments in a final report.
Samsung Bioepis Report Signals Turning Point for US Biosimilars
May 1st 2025A wave of biosimilar approvals, aggressive pricing strategies, and a regulatory sea change are setting the stage for unprecedented momentum in the US biologics market, with 2025 already proving to be a landmark year in reshaping cost, access, and innovation across therapeutic areas.
Will the FTC Be More PBM-Friendly Under a Second Trump Administration?
February 23rd 2025On this episode of Not So Different, we explore the Federal Trade Commission’s (FTC) second interim report on pharmacy benefit managers (PBMs) with Joe Wisniewski from Turquoise Health, discussing key issues like preferential reimbursement, drug pricing transparency, biosimilars, shifting regulations, and how a second Trump administration could reshape PBM practices.
Biosimilar Market Development Requires Strategic Flexibility and Global Partnerships
April 29th 2025Thriving in the evolving biosimilar market demands bold collaboration, early global partnerships, and a fresh approach to development strategies to overcome uncertainty and drive future success.
Biosimilars Policy Roundup for September 2024—Podcast Edition
October 6th 2024On this episode of Not So Different, we discuss the FDA's approval of a new biosimilar for treating retinal conditions, which took place in September 2024 alongside other major industry developments, including ongoing legal disputes and broader trends in market dynamics and regulatory challenges.
BioRationality: EMA Accepts Waiver of Clinical Efficacy Testing of Biosimilars
April 21st 2025Sarfaraz K. Niazi, PhD, shares his latest citizen's petition to the FDA, calling on the agency to waive clinical efficacy testing in response to the European Medicines Agency's (EMA) efforts towards the same goal.
President Trump Signs Executive Order to Bring Down Drug Prices
April 16th 2025To help bring down sky-high drug prices, President Donald Trump signed an executive order pushing for faster biosimilar development, more transparency, and tougher rules on pharmacy benefit managers—aiming to save billions and make meds more affordable for everyone.